This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Jubilant Pharma Holdings Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Nagabasayya R Chikkamath: Innovator in Pharmaceutical Compositions
Introduction
Nagabasayya R Chikkamath is a notable inventor based in Noida, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injection compositions for treating metabolic diseases.
Latest Patents
Chikkamath holds a patent for a parenteral dosage form of β3 adrenoreceptor agonists. This patent discloses injection compositions of β3 adrenoreceptor agonists, such as mirabegron, along with their pharmaceutically acceptable salts, solvates, or esters. The invention outlines methods for preparing these injection compositions and their application in treating obesity and related metabolic diseases. The compositions are designed for easy preparation and application, ensuring better absorption and effectiveness, especially in cases where oral administration is not feasible.
Career Highlights
Chikkamath is associated with Jubilant Pharma Holdings Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on enhancing drug delivery systems and improving patient outcomes through advanced formulations.
Collaborations
He collaborates with talented professionals in his field, including Indranil Nandi and Tusharmouli Mukherjee, to drive forward innovative solutions in pharmaceuticals.
Conclusion
Nagabasayya R Chikkamath's contributions to pharmaceutical innovations highlight his commitment to improving healthcare through effective drug delivery systems. His work continues to impact the treatment of metabolic diseases positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile